Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Clinical Data, Inc. (NASDAQ: CLDA) (referred to as "Clinical Data" or the “Company”) by Forest Laboratories, Inc. (“Forest”) in a cash transaction valued at approximately $1.2 billion.

Under the terms of the agreement, Forest will commence a cash tender offer to purchase all of the outstanding shares of Clinical Data common stock for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd (vilazodone HCL tablets), a treatment for adults with major depressive disorder which was developed by Clinical Data and approved by the U.S. Food and Drug Administration on January 21, 2011.

Bull & Lifshitz, LLP's investigation is focused on whether the proposed deal provides adequate value to the Company’s shareholders. If you are a holder of Clinical Data stock and want to discuss your legal rights, you may e-mail or call Bull & Lifshitz, LLP who will, without obligation or cost to you, attempt to answer your questions.

If you are a shareholder of Clinical Data and would like more information about our investigation, please contact Peter D. Bull, Esq. by telephone at (866) 313-6222 or by sending an e-mail including your contact information to: counsel@nyclasslaw.com. All e-mail correspondence should make reference to Clinical Data.

Bull & Lifshitz, LLP is a New York City-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at www.nyclasslaw.com.

ATTORNEY ADVERTISING . © 2011 Bull & Lifshitz, LLP. The law firm responsible for this advertisement is Bull & Lifshitz, LLP, 18 East 41 st Street, New York, New York 10017, (212) 213-6222. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

If you liked this article you might like

Insider Trading, David Sokol: Hot Trends

Insider Trading, David Sokol: Hot Trends

FDA Chemist Charged With Insider Trading

FDA Chemist Charged With Insider Trading

Biotech Stock Mailbag: Exact Sciences

Biotech Stock Mailbag: Exact Sciences

Clinical Data Stock Falls On Unusually High Volume (CLDA)

Clinical Data Stock Falls On Unusually High Volume (CLDA)

Forest Labs 'Takes Under' Clinical Data

Forest Labs 'Takes Under' Clinical Data